Our previous reports demonstrate that PRL3 antibody therapy can inhibit PRL3+ tumors in multiple animal models using cancer cell lines derived from different origins, including ovarian, colorectal, melanoma, lung, AML, and gastric tissues (Supplementary Table 1). This evidence concerns the gene PTP4A3 and cancer.